A pilot trial assessing Leronlimab in HIV patients with cancer who require bone marrow transplantation
Latest Information Update: 23 May 2024
Price :
$35 *
At a glance
- Drugs Leronlimab (Primary)
- Indications Cancer; HIV infections
- Focus Therapeutic Use
- Sponsors CytoDyn
- 01 Feb 2024 According to a CytoDyn media release, company announced that it has submitted its revised HIV clinical trial protocol to the FDA and company believes that this submission will lead to the removal of the clinical hold currently in effect.
- 30 Mar 2022 According to a CytoDyn media release, the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on Leronlimab HIV program.The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved.
- 30 Mar 2022 Status changed from planning to suspended, according to a CytoDyn media release.